London-based GlaxoSmithKline plc snagged a next-generation T-cell vaccine platform and several promising early stage candidates in its buyout of Swiss firm Okairos AG for €250 million (US$323.8 million).
Salix Pharmaceuticals Ltd. said its two pivotal studies of budesonide foam in active to moderate ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS) hit the primary endpoints, with a statistically significant number of patients in the treatment arm achieving clinical remission vs. placebo.
For more than half a decade, researchers have understood translation to be a key step in gene expression, but it's only recently that drugmakers have begun looking at restoring translational control as a means of treating disease.
As sales of Incyte Corp.'s approved JAK inhibitor Jakafi (ruxolitinib) begin to pick up steam, a competing myelofibrosis candidate from Sanofi SA moved a step closer to market.
Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc. barely two months ago, Ambit Biosciences Corp. forged ahead with its initial public offering (IPO). The San Diego-based biotech priced about 8.1 million shares at $8 apiece for gross proceeds of about $65 million.
Development of Tokai Pharmaceuticals Inc.'s triple-acting prostate cancer drug galeterone got a $35.5 million boost, with the Cambridge, Mass.-based biotech closing a Series E round with current investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.
Dyax Corp. is more than doubling its cash position with a $30 million registered direct offering, with proceeds to fund R&D activities, namely clinical development of DX-2930, a drug slated to start clinical development for prophylactic use in hereditary angioedema (HAE).
Practically overnight, Affymax Inc. went from being lauded as a biotech success story and Wall Street darling to become one of the sector's biggest disappointments, and now, according to the latest 10-Q filing, the Palo Alto, Calif.-based firm might be nearing its end.
Shares of Alexza Pharmaceuticals Inc. jumped 29 percent Wednesday after the firm disclosed a U.S. commercialization partner for recently approved Adasuve, a version of antipsychotic drug loxapine delivered via the company's Staccato technology.
In the wake of promising preclinical data for its hepatitis B virus (HBV) candidate, Arrowhead Research Corp. shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection.
